High-dose Therapy with Single Autologous Transplantation versus Chemotherapy for Newly Diagnosed Multiple Myeloma: A Systematic Review and Meta-analysis.

Slides:

Advertisements

Similar presentations

Date of download: 7/7/2016 Copyright © 2016 American Medical Association. All rights reserved. From: Allogeneic Stem Cell Transplantation for Acute Myeloid.

Advertisements

Controversies in multiple myeloma: Evidence-based update

Systematic Review of Controlled Clinical Trials on the Use of Ursodeoxycholic Acid for the Prevention of Hepatic Veno-occlusive Disease in Hematopoietic.

Divergent Effects of Novel Immunomodulatory Agents and Cyclophosphamide on the Risk of Engraftment Syndrome after Autologous Peripheral Blood Stem Cell.

Perioperative Blood Transfusion Is Associated With Worse Clinical Outcomes in Resected Lung Cancer Ting Wang, MD, Lili Luo, MD, He Huang, MD, Jingrui.

Relative Survival of Long-Term Hematopoietic Cell Transplant Recipients Approaches General Population Rates Ian Nivison-Smith, Judy M. Simpson, Anthony.

Nikolaos P. Polyzos, M. D. , Christina I. Messini, M. D. , Evangelos G

How to Treat MDS without Stem Cell Transplantation

The Effect of Statin Use at the Time of Autologous Transplant on Response and Survival in Multiple Myeloma Mehdi Hamadani, Erinn Hade, Don M. Benson,

Long-Term Outcome of Patients with Metastatic Breast Cancer Treated with High-Dose Chemotherapy and Transplantation of Purified Autologous Hematopoietic.

Content of Endothelial Progenitor Cells in Autologous Stem Cell Grafts Predict Survival after Transplantation for Multiple Myeloma Egil S. Blix, Anders.

Biology of Blood and Marrow Transplantation

Efficacy of Rituximab in the Setting of Steroid-Refractory Chronic Graft-versus-Host Disease: A Systematic Review and Meta-Analysis Mohamed A. Kharfan-Dabaja,

Influence of Stem Cell Source on Outcomes of Allogeneic Reduced-Intensity Conditioning Therapy Transplants Using Haploidentical Related Donors Kenneth.

Improved Treatment-Related Mortality and Overall Survival of Patients with Grade IV Acute GVHD in the Modern Years Areej El-Jawahri, Shuli Li, Joseph.

Bradley W. Blaser, Haesook T. Kim, Edwin P. Alyea, Vincent T

A 15-Year Analysis of Early and Late Autologous Hematopoietic Stem Cell Transplant in Relapsed, Aggressive, Transformed, and Nontransformed Follicular.

Outcomes of Allogeneic Stem Cell Transplantation in Elderly Patients with Acute Myeloid Leukemia: A Systematic Review and Meta-analysis Armin Rashidi,

Prediction of Veno-Occlusive Disease Using Biomarkers of Endothelial Injury Corey Cutler, Haesook T. Kim, Shaké Ayanian, Gary Bradwin, Carolyn Revta,

A Phase II Study of Bortezomib Plus Prednisone for Initial Therapy of Chronic Graft- versus-Host Disease Alex F. Herrera, Haesook T. Kim, Bhavjot Bindra,

Perioperative Blood Transfusion Is Associated With Worse Clinical Outcomes in Resected Lung Cancer Ting Wang, MD, Lili Luo, MD, He Huang, MD, Jingrui.

Allogeneic Transplantation with Reduced-Intensity Conditioning for Hodgkin and non- Hodgkin Lymphoma: Importance of Histology for Outcome Philippe Armand,

First- and Second-Line Systemic Treatment of Acute Graft-versus-Host Disease: Recommendations of the American Society of Blood and Marrow Transplantation

Sabina Kersting, Leo F. Verdonck

Randomized trial of allogeneic related bone marrow transplantation versus peripheral blood stem cell transplantation for chronic myeloid leukemia Vivian.

Role of High-Dose Chemotherapy and Autologous Hematopoietic Cell Transplantation in Primary Systemic Amyloidosis: A Systematic Review Rahul Mhaskar,

Phase II Trial of Tandem High-Dose Chemotherapy with Autologous Stem Cell Transplantation Followed by Reduced-Intensity Allogeneic Stem Cell Transplantation.

Outcome and Prognostic Factors for Patients Who Relapse after Allogeneic Hematopoietic Stem Cell Transplantation Gita Thanarajasingam, Haesook T. Kim,

Extracorporeal Photopheresis in Steroid-Refractory Acute or Chronic Graft-versus-Host Disease: Results of a Systematic Review of Prospective Studies

Decision Analysis of Peripheral Blood versus Bone Marrow Hematopoietic Stem Cells for Allogeneic Hematopoietic Cell Transplantation Joseph Pidala, Claudio.

Busulfan Dose Intensity and Outcomes in Reduced-Intensity Allogeneic Peripheral Blood Stem Cell Transplantation for Myelodysplastic Syndrome or Acute.

Jennifer Crombie, Laura Spring, Shuli Li, Robert J. Soiffer, Joseph H

New Light Chain Amyloid Response Criteria Help Risk Stratification of Patients by Day 100 after Autologous Hematopoietic Cell Transplantation Anita D'Souza,

Impact of Cytogenetics on Outcome of De Novo and Therapy-Related AML and MDS after Allogeneic Transplantation Philippe Armand, Haesook T. Kim, Daniel.

Seroprotective Titers against 2009 H1N1 Influenza A Virus after Vaccination in Allogeneic Hematopoietic Stem Cell Transplantation Recipients Nicolas.

Intravenous Busulfan and Melphalan as a Conditioning Regimen for Autologous Stem Cell Transplantation in Patients with Newly Diagnosed Multiple Myeloma:

John Kuruvilla, John D. Shepherd, Heather J. Sutherland, Thomas J

A systematic review and meta-analysis of stereotactic body radiation therapy versus surgery for patients with non–small cell lung cancer Christopher.

Absolute Lymphocyte Count Recovery after Allogeneic Hematopoietic Stem Cell Transplantation Predicts Clinical Outcome Haesook T. Kim, Philippe Armand,

Sarah A. Holstein, Paul G. Richardson, Jacob P. Laubach, Philip L

The Role of Cytotoxic Therapy with Hematopoietic Stem Cell Transplantation in the Therapy of Acute Myelogenous Leukemia in Adults: An Evidence-Based Review

Favorable Overall Survival with Fully Myeloablative Allogeneic Stem Cell Transplantation for Follicular Lymphoma John Kuruvilla, Gregory Pond, Richard.

Kamal Kant Singh Abbi, Junting Zheng, Sean M

Autologous Stem Cell Transplantation Is an Effective Salvage Therapy for Primary Refractory Multiple Myeloma Christopher Parrish, Amin Rahemtulla, Jim.

An Open-Label Phase II Randomized Trial of Topical Dexamethasone and Tacrolimus Solutions for the Treatment of Oral Chronic Graft-versus-Host Disease

Comparison of Tacrolimus and Sirolimus (Tac/Sir) versus Tacrolimus, Sirolimus, and Mini-Methotrexate (Tac/Sir/MTX) as Acute Graft-versus-Host Disease.

Outcomes of Maintenance Therapy with Bortezomib after Autologous Stem Cell Transplantation for Patients with Multiple Myeloma Dharshan Sivaraj, Michael.

Single Center Experience with High Dose Melphalan and Two Day Washout in Patients with Multiple Myeloma on Hemodialysis Undergoing Autologous Stem Cell.

Adverse Prognostic Factors for Morbidity and Mortality During Peripheral Blood Stem Cell Mobilization in Patients with Light Chain Amyloidosis Jason.

Regression Models for Hazard Rates Versus Cumulative Incidence Probabilities in Hematopoietic Cell Transplantation Data Brent R. Logan, Mei-Jie Zhang,

Akiko M. Saito, Corey Cutler, David Zahrieh, Robert J

Incidence of Adrenal Insufficiency in Patients with Multiple Myeloma during High Dose Chemotherapy and Autologous Stem Cell Transplant Ahmad Hatem Mattour,

Tbo-Filgrastim versus Filgrastim during Mobilization and Neutrophil Engraftment for Autologous Stem Cell Transplantation Mohammed M. Elayan, Justin G.

What is quality in a transplant program?

The Impact of Geographic Proximity to Transplant Center on Outcomes after Allogeneic Hematopoietic Stem Cell Transplantation Karim E. Abou-Nassar, Haesook.

Reduced-Intensity Conditioning Hematopoietic Stem Cell Transplantation in Patients Over 60 Years: Hematologic Malignancy Outcomes Are Not Impaired in Advanced.

A Prognostic Score for Patients with Acute Leukemia or Myelodysplastic Syndromes Undergoing Allogeneic Stem Cell Transplantation Philippe Armand, Haesook.

Bernard Maybury, Gordon Cook, Guy Pratt, Kwee Yong, Karthik Ramasamy

The role of cytotoxic therapy with hematopoietic stem cell transplantation in the therapy of multiple myeloma: An evidence-based review Theresa Hahn,

John Koreth, Edwin P. Alyea, William J. Murphy, Lisbeth A. Welniak

Mammen Chandy Biology of Blood and Marrow Transplantation

Impact of Pretransplantation Indices in Hematopoietic Stem Cell Transplantation: Knowledge of Center-Specific Outcome Data Is Pivotal before Making Index-Based.

Treatment versus Transplant for Challenging Hematologic Disorders

Mary Eapen Biology of Blood and Marrow Transplantation

Futility of Relapsed Diffuse Large B Cell Lymphoma Transplantation?

In Memoriam: E. Donnall Thomas

Long-Term Results Of Autologous Hematopoietic Cell Transplantation For Peripheral T Cell Lymphoma: The Stanford Experience Andy I. Chen, Alex McMillan,

Disparities in Utilization of Autologous Hematopoietic Cell Transplantation for Treatment of Multiple Myeloma Luciano J. Costa, Jia-Xing Huang, Parameswaran.

Iron Overload in Patients with Acute Leukemia or MDS Undergoing Myeloablative Stem Cell Transplantation Philippe Armand, Haesook T. Kim, Joanna Rhodes,

Early Clinical Predictors of Hepatic Veno-Occlusive Disease/Sinusoidal Obstruction Syndrome after Myeloablative Stem Cell Transplantation Lindsey E.

Presentation transcript:

High-dose Therapy with Single Autologous Transplantation versus Chemotherapy for Newly Diagnosed Multiple Myeloma: A Systematic Review and Meta-analysis of Randomized Controlled Trials John Koreth, Corey S. Cutler, Benjamin Djulbegovic, Rajesh Behl, Robert L. Schlossman, Nikhil C. Munshi, Paul G. Richardson, Kenneth C. Anderson, Robert J. Soiffer, Edwin P. Alyea Biology of Blood and Marrow Transplantation Volume 13, Issue 2, Pages 183-196 (February 2007) DOI: 10.1016/j.bbmt.2006.09.010 Copyright © 2007 American Society for Blood and Marrow Transplantation Terms and Conditions

Figure 1 Search strategy flow chart. The Embase, Pubmed, and Cochrane database search and the process of identifying relevant randomized controlled trials (RCTs) for inclusion in the meta-analysis are shown. Note that the studies excluded on text review were often ineligible for multiple reasons; hence, the total number of exclusions is larger than the number of studies excluded. *One publication, a meta-analysis of 3 RCTs, provided updated hazard ratio information on overall survival benefit of high-dose therapy and single autologous stem cell transplantation (HDT) and was used in the analysis. SDT indicates nonmyeloablative standard-dose therapy. Biology of Blood and Marrow Transplantation 2007 13, 183-196DOI: (10.1016/j.bbmt.2006.09.010) Copyright © 2007 American Society for Blood and Marrow Transplantation Terms and Conditions

Figure 2 Forrest plot of overall survival (OS) benefit of upfront high-dose therapy and single autologous stem cell transplantation (HDT) in myeloma. The individual randomized controlled trials (RCTs) are indicated on the y axis. The summary effect estimate (hazard ratio [HR]) for individual RCTs are indicated by black rectangles (the size of the rectangle is proportional to the study weight), with the lines representing 95% confidence intervals (CIs). The overall summary effect estimate (HR) and 95% CI are indicated by the diamond below. Overall estimates after sensitivity and subgroup analyses are shown below. The corresponding values for HR (95% CI) are indicated alongside. *Nonstandard study. ‡ Two negative studies (HOVON, IFM9906) with missing crossover information were omitted from this analysis. PBSC indicates peripheral blood stem cell; SDT, nonmyeloablative standard-dose therapy. Biology of Blood and Marrow Transplantation 2007 13, 183-196DOI: (10.1016/j.bbmt.2006.09.010) Copyright © 2007 American Society for Blood and Marrow Transplantation Terms and Conditions

Figure 3 Forrest plot of progression-free survival (PFS) benefit of upfront high-dose therapy and single autologous stem cell transplantation (HDT) in myeloma. The individual randomized controlled trials (RCTs) are indicated on the y axis. The summary effect estimate (hazard ration [HR]) for individual RCTs are indicated by black rectangles (the size of the rectangle is proportional to the study weight), with lines representing 95% confidence intervals (CIs). The overall summary effect estimate (HR) and 95% CI are indicated by the diamond. Overall estimates after additional sensitivity and subgroup analyses are shown below. The corresponding values for HR (95% CI) are indicated alongside. * Nonstandard study. ‡ Two negative studies (HOVON, IFM9906) with missing crossover information were omitted from this analysis. PBSC indicates peripheral blood stem cell; SDT, nonmyeloablative standard-dose therapy. Biology of Blood and Marrow Transplantation 2007 13, 183-196DOI: (10.1016/j.bbmt.2006.09.010) Copyright © 2007 American Society for Blood and Marrow Transplantation Terms and Conditions

Figure 4 Forrest plot of treatment-related mortality risk of upfront high-dose therapy and single autologous stem cell transplantation (HDT) in myeloma. The individual randomized controlled trials (RCTs) are indicated on the y axis. The summary effect estimate (odds ratio) for individual RCTs are indicated by black rectangles (the size of the rectangle is proportional to the study weight), with lines representing 95% confidence intervals (CIs). The overall summary effect estimate (odds ratio) and 95% CI are indicated by the diamond. SDT indicates nonmyeloablative standard-dose therapy. Biology of Blood and Marrow Transplantation 2007 13, 183-196DOI: (10.1016/j.bbmt.2006.09.010) Copyright © 2007 American Society for Blood and Marrow Transplantation Terms and Conditions